Opinion|Videos|June 10, 2025

The Use of Ultra-Low PSA in Specific Patient Profiles

Research explores the effectiveness of Aerote in treating metastatic hormone-sensitive prostate cancer, focusing on patient subgroups and genetic factors.

Patient Selection for Ultra-Low PSA Monitoring

Key Themes:

  • Identification of patient profiles most likely to benefit from ultra-low PSA monitoring
  • Relevance for specific risk categories
  • Potential applications in high-volume disease or triplet therapy

Expert Insights:

  • Dr Shore identified specific patient profiles or risk categories where the ultra-low PSA threshold might be particularly valuable.

He discussed its potential relevance for patients with high-volume disease, those receiving triplet therapy, or patients demonstrating rapid initial PSA declines.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


Latest CME